Seagen Inc (NASDAQ:SGEN)

Stock Price: $196.60
+1.88 (0.97%)
Updated Jun 9, 2023 08:00 PM GMT+0000
Featured app
eToro
Invest now

77% of retail CFD accounts lose money.

Overview
Financials
Statistics
Profile
Chart
Market Cap 36.86B
Revenue 2.06B
Gross Profit 1.62B
Shares Out 187.50M
EPS (ttm) -3.5
PE Ratio -56.8395
Forward PE -65.8801
Dividend Rate (ttm) 0.0000
Dividend Yield 0.0000
Trading Day Jun 9
Last Price $196.60
Previous Close $194.72
Change ($) 1.88
Change (%) 0.97%
Day's Open 194.43
Day's Range 194.01 - 198.66
Day's Volume 1.87M
52 Week Range 116.08 - 207.17

About Seagen Inc

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings.

seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys.

News

Quick info

Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Employees
3,256
Ticker Symbol
SGEN
Reporting Currency
USD